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The cell culture-adapted KyA strain of equine herpesvirus type 1 (EHV-1) has been found to be attenuated in young horses
(Matsumura et al., 1996, Vet. Microbiol. 48, 353–365). The KyA strain lacks at least six genes in its genome, including those
encoding glycoproteins gE and gI. To elucidate whether EHV-1 glycoproteins gE and gI play a role in viral virulence, we have
constructed an EHV-1 recombinant that has the genes encoding both gE and gI deleted from its genome and its revertant.
Growth properties of the deletion mutant virus in vitro were compared with those of the parent and the revertant viruses.
Plaque size of the mutant virus in fetal horse kidney (FHK) cells was significantly smaller than those of the parent and the
revertant viruses. In one-step growth experiments, however, the yields of infectious virus from FHK cells infected with the
deletion mutant, the parent, or the revertant virus were approximately the same. The results suggested that gE and/or gI of
EHV-1 promoted cell-to-cell spread of the virus, but that these glycoproteins were not involved in the process of virus
maturation and release or in virus attachment and penetration. Subsequently, the virulence of mutant and revertant viruses
was examined in young horses. No clinical signs were observed in six horses, including three colostrum-deprived foals
inoculated intranasally with the deletion mutant virus, whereas three colostrum-deprived foals inoculated intranasally with
the revertant virus manifested clinical signs typical for EHV-1 respiratory infection (i.e., pyrexia, nasal discharge, and swelling
of submandibular lymph nodes). The results obtained from in vivo studies revealed that the EHV-1 mutant defective in both
gE and gI genes was avirulent in young horses, suggesting that gE and/or gI of the EHV-1 have an important role in EHV-1
virulence. However, the EHV-1 mutant defective in both gE and gI genes induced only a partial protectivity in inoculated foals
from manifestation of respiratory symptoms after challenge infection. © 1998 Academic Press
INTRODUCTION
Equine herpesvirus type 1 (EHV-1), a member of the
Alphaherpesvirus subfamily, causes abortion and ner-
vous disorder in susceptible mares and epizootic respi-
ratory disease in racehorses (Allen and Bryans, 1986;
Mason et al., 1989; Matsumura et al., 1992; O’Callaghan
and Osterrieder, 1998). When widely distributed, EHV-1
causes serious economic loss in the horse industry
worldwide. Although vaccines against EHV-1 are avail-
able, their efficacy is limited (Burrows et al., 1984; Bu¨rki
et al., 1990). Progress in genetic engineering technology
has allowed the construction of Alphaherpesviruses that
are attenuated due to the deletion of DNA sequences
essential for viral virulence (Kimman et al., 1992; van
Engelenburg et al., 1994; Kaashoek et al., 1996; Kruger et
al., 1996; Yokoyama et al., 1996). Such recombinant vi-
ruses would be candidates for development of an effec-
tive live vaccine that could stimulate both antibody and
cellular immune responses important in the protection
against herpesvirus infection (Rouse and Horohov, 1984).
A vaccine against EHV-1, in addition, should be com-
pletely safe, since it would be inoculated into race-
horses, which are delicate animals to maintain in excel-
lent condition for races. For development of an effective
and safe live EHV-1 vaccine, it is important to determine
the functions necessary for viral pathogenicity. However,
knowledge concerning the genetic basis for the viru-
lence of EHV-1 is limited. Among the 76 genes deduced
from the complete DNA sequence of the EHV-1 Ab4p
strain (Telford et al., 1992), genes 67 (IR6) and 71 (EUS4)
have been associated with the virulence of EHV-1 for
mice (Osterrieder et al., 1996; Marshal et al., 1997). To
date, gene 38, which encodes thymidine kinase (TK), is
the only gene confirmed associated with the virulence of
EHV-1 for the natural host, horses (Cornick et al., 1990;
Slater et al., 1993), although an EHV-1 TK-deficient mu-
tant still exhibits mild virulence for specific pathogen-free
(SPF) foals (Slater et al., 1993).
Recent studies revealed that a laboratory strain of
EHV-1, Kentucky A (KyA), has no virulence for horses
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(Matsumura et al., 1996) or for mice (Colle et al., 1996).
Due to extensive passage in nonequine cells (Flowers
and O’Callaghan, 1992) and in hamsters (Randall and
Lawson, 1962), the KyA strain has lost at least six genes
(genes 1, 2, 17, 73, 74, and 75) compared with the
genomic sequence of the EHV-1 Ab4p strain (Yalaman-
chili and O’Callaghan, 1990; Yalamanchili et al., 1990;
Flowers and O’Callaghan, 1992; Telford et al., 1992; Ma-
tsumura et al., 1993). Gene 17, a homolog of varicella
zoster virus (VZV) gene 15, encodes a particularly hydro-
phobic protein containing a periodic charge pattern (Kar-
lin et al., 1989; Telford et al., 1992). Gene 1 has a homolog
in pseudorabies virus (PRV) (Baumeister et al., 1995), and
gene 75 has positional homologs in herpes simplex virus
type 1 (HSV-1) (Georgopoulou et al., 1993) and feline
herpesvirus type 1 (FHV-1) (Willemse et al., 1995), al-
though no definite functions of proteins encoded by
genes 1 and 75 as well as gene 2 have yet been eluci-
dated. On the other hand, genes 73 and 74 encode
glycoproteins gI and gE, respectively (Audonnet et al.,
1990; Elton et al., 1991; Telford et al., 1992), homologs of
which are associated with viral virulence in Alphaher-
pesviruses. HSV-1 mutants unable to express gE or gI
failed to induce corneal disease or encephalitis in mice
following corneal inoculation (Dingwell et al., 1994). Gly-
coproteins gI and gp63 of PRV, homologs of gE and gI of
HSV-1, respectively, play a role in the invasion and
spread of virus in the nervous system of pigs (Kritas et
al., 1994). Furthermore, deletion of the gE gene of BHV-1
or the gE and gI genes of FHV-1 reduced viral virulence
in the natural hosts, bovine and feline, respectively (van
Engelenburg et al., 1994; Sussman et al., 1995; Kruger et
al., 1996). Thus, we have expected that the lack of gE and
gI genes in the KyA genome would contribute to an
attenuated nature of the KyA strain.
In this paper, we describe the construction of a gE and
gI deletion mutant from a virulent EHV-1 strain and its
revertant and report the features of the mutant and re-
vertant viruses exhibited in vitro and in vivo. In vitro
studies suggested that the gE and/or gI of EHV-1 facili-
tated cell-to-cell virus spread. Furthermore, in vivo stud-
ies revealed that the gE and gI deletion mutant of EHV-1
was avirulent for horses and that the revertant virus
rescued the inherent virulence of EHV-1 for foals.
RESULTS
Construction of a gE and gI deletion mutant and
its revertant
To construct a deletion–insertion vector, plasmid
pSma-Bam containing EHV-1 genes for gD, gI, gE, and 75
was digested with BalI and PmaCI to remove 2747 nu-
cleotides (nt 132,902 to 135,648 of EHV-1 Ab4p strain;
GenBank Accession No. M86664) that contain most of
the coding sequences for the gI and gE genes (Fig. 1).
The flanking sequence was ligated with the blunt-ended
4.2-kb DNA fragment, containing the E. coli lacZ gene
and the SV40 early promoter, which was obtained by
digestion of pCH110 with Tth111I and BamHI. The result-
ing plasmid, designated pDgEDgI-lacZ, lacks 1271 of
1275 bp and 1244 of 1653 bp of the EHV-1 gI and gE
sequences, respectively. Insertion of lacZ gene in the
opposite direction to the gD, gI, gE, and 75 genes of
EHV-1 resulted in the generation of a new BamHI recog-
nition site at the junction site of the BalI end of EHV-1 and
the BamHI end of pCH110 (Fig. 1B). An EHV-1 virus stock
containing the lacZ-positive mutant was obtained by
transfection of pDgEDgI-lacZ DNA into FHK cells in-
fected with the 89c25p strain. Purification of the EHV-1
mutant was achieved after four repetitive procedures of
blue plaque cloning, and the resulting mutant was des-
ignated DgEDgI-lacZ. Construction and purification of a
revertant virus were similarly achieved by transfecting
pSma-Bam DNA into FHK cells infected with the DgEDgI-
lacZ strain and by repetitive procedures of white plaque
FIG. 1. Diagram of the EHV-1 genome. (A) The BamHI restriction map of the EHV-1 HH-1 strain (Kirisawa et al., 1993b). (B) The 5.8-kb SmaI–BamHI
fragment cloned into pUC vector (pSma-Bam) is expanded, showing relevant restriction sites (B, BamHI; Ba, BalI; E, EcoRI; P, PmaCI; S, SmaI). The
locations and direction of ORF 75 and genes encoding gD, gI, and gE are indicated with arrows. Shown below is the construction of deletion–insertion
vector (pDgEDgI-lacZ) derived from pSma-Bam, in which the location and direction of lacZ gene insertion are indicated. By the insertion, a BamHI
recognition site is newly generated in pDgEDgI-lacZ.
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cloning, respectively. The resulting revertant was desig-
nated gE-gI-rev.
By PCR using gE, gI, and lacZ-1 primer sets (Table 1),
only the lacZ product was amplified from DgEDgI-lacZ
DNA, while the gE and gI products but no lacZ product
were amplified from gE-gI-rev DNA. DNA sequence anal-
yses using sequence primers listed in Table 1 revealed
that the pCH110-derived sequence was inserted in the
appropriate location on the DgEDgI-lacZ genome and
that no alteration was observed in the EHV-1 sequences
around the junction sites (SmaI, BalI(BamHI), PmaCI, and
BamHI sites; see Fig. 1) of the DgEDgI-lacZ compared to
the corresponding sequences of the parent 89c25p
strain and the Ab4p strain of EHV-1 (Telford et al., 1992).
In Southern blot analysis on BamHI digests of viral
DNAs, furthermore, the pSma-Bam DNA probe hybrid-
ized to two fragments of DgEDgI-lacZ DNA, a 6.4- and a
5.6-kb fragment, as expected from the newly generated
BamHI recognition site by the insertion of the pCH110-
derived sequence and to a single 10.5-kb BamHI D frag-
ment of 89c25p and gE-gI-rev DNAs (Fig. 2). DIG-labeled
pCH110 DNA failed to hybridize to any fragment of
89c25p and gE-gI-rev DNAs, but hybridized to the 5.6-kb
fragment of DgEDgI-lacZ DNA (data not shown). These
results confirmed that the DgEDgI-lacZ genome lacked
the 2747 nucleotides from the fifth nucleotide of the gI
open reading frame (ORF) to nucleotide 1244 of the gE
ORF, including the entire noncoding sequence (232 nt)
located between the gI and gE ORFs, and that the de-
leted EHV-1 sequence in the DgEDgI-lacZ genome was
rescued in the gE-gI-rev genome.
Growth properties of EHV-1 strains in vitro
In experiments concerning viral growth, the KyA strain
of EHV-1 was used as a reference strain, as the KyA
genome lacks gE and gI genes by a 3859-bp deletion
from nt 132,811 to 136,669 relative to the sequence of
TABLE 1
Nucleotide Sequences of Primers for PCR and Sequencing
Primers Sequence Locationa
EHV-1
Sma sequence up 59-GCTTGCCCCACGAATCTAGT 131,001–131,020
Sma sequence down 59-CAAGCAGCACAGCAGGCATA 131,450–131,431
Deletion sequence up 59-ATCAGCGTCGGTTTGGGTATCG 132,635–132,656
Deletion sequence down 59-TCATACGGCTTACGGTTGCTTC 135,723–135,702
Bam sequence up 59-CGACCAAGAAGTAAGCGAAG 136,859–136,878
Bam sequence down 59-CGACGACACAACCACCATCT 137,120–137,101
gI up 59-GAATCATGCCCGCGTGTAGCCA 133,174–133,195
gI down 59-GTGCAGGCGATGTGGTACGAAG 133,768–133,747
gE up 59-AGTCACATATCGTAGAGCCCAG 135,072–135,093
gE down 59-CTACAGATGGATGAGGAGTGAT 135,581–135,560
gB FC2b 59-CTTGTGAGATCTAACCGCAC 62,908–62,927
gB RC (reverse)b 59-GGGTATAGAGCTTTCATGGG 64,088–64,069
gB FC3b 59-ATACGATCACATCCAATCCC 63,180–63,199
gB R1 (reverse)b 59-GCGTTATAGCTATCACGTCC 63,367–63,348
pCH110
lacZ-Bam sequence 59-GCTATTTCTCTGTTCTCGCTAT 3544–3565
lacZ-Tth sequence 59-GTGAAAACCTCTGACACATGCA 6758–6737
lacZ-1 up 59-GACCAGAAACAGCACCTCGAAC 220–241
lacZ-1 down 59-GGTTTTCTCCGGCGCGTAAAAA 817–796
lacZ-3 up 59-ACATCCCCCTTTCGCCAGCT 357–376
lacZ-3 down 59-TGCACCACAGATGAAACGCCG 733–713
a Nucleotide numbers of EHV-1 and pCH110 primers correspond to the complete sequences of EHV-1 Ab4p strain (GenBank Accession No.
M86664) and pCH110 (GenBank Accession No. U13845), respectively.
b Primers for nested PCR to detect EHV-1 gB gene were synthesized according to the published sequences described by Kirisawa et al. (1993a).
FIG. 2. Southern blot analysis of EHV-1 DNAs digested with BamHI
and probed with pSma-Bam (Fig. 1). Digested DNAs were electropho-
resed through 0.7% agarose gels for 18.5 h at 20 V, stained with
ethidium bromide, photographed, and then transferred to nylon mem-
brane. Lane 1, gE-gI-rev DNA; lane 2, 89c25p DNA; and lane 3, DgEDgI-
lacZ DNA. The sizes of molecular markers are indicated on the left.
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EHV-1 Ab4p strain (Flowers and O’Callaghan, 1992; Tel-
ford et al., 1992). Since the gE and gI genes of other
herpesviruses have been associated with the cell-to-cell
spread of virus, the plaque size of the DgEDgI-lacZ was
compared to that of the parent 89c25p, the revertant
gE-gI-rev, and the KyA strains in FHK cells. The average
sizes of 20 plaques formed after 3 and 5 days cultivation
of the strains lacking gE and gI genes, DgEDgI-lacZ and
KyA, were significantly smaller (P , 0.0001) than those of
the intact EHV-1 strains, 89c25p and gE-gI-rev (Table 2).
Moreover, a significant difference in the average sizes of
plaques was also observed between the deletion strains,
DgEDgI-lacZ and KyA (P , 0.0001). No difference was
observed statistically between the plaque sizes of
89c25p and gE-gI-rev strains. These results suggested
that the gE and/or gI play an important role in cell-to-cell
viral spread for EHV-1 as shown for other herpesviruses.
Next, a one-step growth experiment of EHV-1 strains
was conducted to examine whether the deletion of the
gE-gI sequences would affect viral growth in FHK and/or
RK13 cells. Cells were infected and harvested at 0, 6, 12,
24, 36, 48, and 72 h postinoculation. Infectivity titers of
extracellular and intracellular viruses at each time were
determined by the plaque titration using FHK cells. The
virus titers of extracellular and intracellular samples from
FHK cells inoculated with DgEDgI-lacZ, 89c25p, or gE-
gI-rev strains reached the peak titers at 48 and 36 h
postinoculation, respectively (Fig. 3). The growth patterns
of these three strains were quite similar, although the
virus titer of the DgEDgI-lacZ extracellular sample at 12 h
postinoculation was higher to some degree than those of
the parent and revertant strains. In contrast, the growth
curves of extracellular and intracellular KyA showed a
rapid increase and reached peak levels at 24 h post-
inoculation, and the extracellular and intracellular titers
of KyA showed the highest value at each time point
among the four strains examined. The results obtained
by using RK13 cells were almost identical to those
obtained by using FHK cells (data not shown). The find-
ing that the DgEDgI-lacZ virus could replicate to almost
the same level as the parent strain in cell cultures con-
TABLE 2
Plaque Size of EHV-1 Strains in FHK Cells
Strain
Days after inoculation
3 5
89c25p 1.92 6 0.20a 3.72 6 0.22
gE-gI-rev 1.86 6 0.18 3.60 6 0.20
DgEDgI-lacZ 0.71 6 0.12 1.45 6 0.23
KyA 1.25 6 0.17 2.36 6 0.24
a Mean 6 standard deviation (n 5 20) of plaque size (mm).
FIG. 3. One-step growth curves of EHV-1 strains in FHK cells. (A) Extracellular and (B) intracellular virus titers (PFU/200 ml). (n) 89c25p; (F)
gE-gI-rev; () DgEDgI-lacZ; and (}) KyA strains.
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firmed that the gE and the gI of EHV-1 are not required for
viral growth in vitro. The remarkable growth property of
the KyA strain in vitro may be due to some other modi-
fications apart from the deletion of the gE and gI genes
on the KyA genome, which has been acquired during a
long history of passage in nonequine cells.
Virulence of the deletion mutant and the revertant
Inoculations of the DgEDgI-lacZ (107.0 PFU/horse) and
the gE-gI-rev strain (5 3 106.0 PFU/foal) were given in-
tranasally to six young horses including three colostrum-
deprived foals (EI-1–EI-6) and three colostrum-deprived
foals (R-1–R-3), respectively. All horses inoculated with
the DgEDgI-lacZ showed no clinical symptoms of respi-
ratory disease (Table 3). In contrast, an obvious elevation
in rectal temperature (^39.0°C) was observed for 4 to 7
days from day 1 or 2 postinoculation in the three foals
(R-1–R-3) inoculated with the gE-gI-rev strain (Table 3;
indicated as control foals). Furthermore, serous to mu-
copurulent nasal discharge was observed for 5, 3, and 7
days from day 4 postinoculation, and swelling of sub-
mandibular lymph nodes was observed for 15, 10, and 14
days from days 3, 5, and 4 postinoculation in foals R-1,
R-2, and R-3, respectively. Clinical signs observed in the
foals inoculated with the gE-gI-rev strain of EHV-1 corre-
sponded well to those in the weanling horses inoculated
with the 89c25 strain of EHV-1 (Matsumura et al., 1996).
These findings indicated that the gE-gI deletion mutant
of EHV-1, DgEDgI-lacZ, was attenuated and that the re-
vertant EHV-1 derived from the DgEDgI-lacZ exhibited
the inherent virulence of EHV-1 to cause a respiratory
disease in foals.
Clinical signs of DgEDgI-lacZ inoculated foals
after challenge
Based on the result that the gE-gI-rev retained viru-
lence for foals, the gE-gI-rev strain of EHV-1 was used as
a challenge virus to examine the protection of the co-
lostrum-deprived foals (EI-4–EI-6) at 4 weeks after inoc-
ulation with the DgEDgI-lacZ strain. The results obtained
from the experimental gE-gI-rev infection in the three
foals were used as control data for this challenge exper-
iment (R-1, R-2, and R-3 were indicated as control foals in
Tables 3–5). After the intranasal challenge with the gE-
gI-rev (5 3 106.0 PFU/foal), serous to mucopurulent nasal
discharge was observed for 7 and 2 days from days 2
and 3 postchallenge in foals EI-5 and EI-6, respectively,
and swelling of submandibular lymph nodes was ob-
served for 8 days from day 5 postchallenge in foal EI-6
(Table 3). These clinical signs were not observed in one
foal, EI-4. However, an obvious elevation in rectal tem-
perature was observed in all foals for 3 to 8 days from
day 1 or 2 postchallenge. These results suggested that
only a partial protection against challenge with patho-
genic EHV-1 was conferred on foals by intranasal inoc-
ulation of the DgEDgI-lacZ.
Virus isolation
After the inoculation with the DgEDgI-lacZ strain, a
mutant strain of EHV-1 confirmed by the lacZ gene ex-
pression and PCR was isolated only from a nasal swab
collected from one (EI-1) of the six horses on day 2
postinoculation (Table 3). No other EHV-1 strain was
isolated even from autopsied samples. These findings
indicated that intranasal inoculation with the gE and gI
deletion mutant of EHV-1 did not result in significant virus
shedding. In additional assays to detect the gE-gI dele-
tion mutant DNA, approximately 10 mg of minced trigem-
inal ganglion, thymus, and lymph nodes samples [10
autopsied samples from each of the horses (EI-1–EI-3)]
were subjected to DNA extraction, and the resulting
samples were examined by nested PCR using the pub-
lished primer sets to detect the EHV-1 gB DNA (Kirisawa
et al., 1993a) and lacZ-1 and lacZ-3 primer sets to detect
TABLE 3
Duration of Clinical Symptoms Observed and of Virus Isolation in Horses after Inoculation with EHV-1 Strains DgEDgI-lacZ and/or gE-gI-rev
Symptoms and results
of virus isolation
Post DgEDgI-lacZ inoculation
(EI-1–EI-6)
Post gE-gI-rev inoculation
DgEDgI-lacZ-inoculated foals
(EI-4–EI-6)
Control foals
(R-1–R-3)
Pyrexia ($39°C) Negative 3 to 8 (5.7 6 2.5)a days 4 to 7 (5.3 6 1.5) days
Nasal discharge Negative 0b to 7 (3.0 6 3.6) days 3 to 7 (5.0 6 2.0) days
Swelling of L.N.c Negative 0d or 8 days 10 to 15 (13.0 6 2.6) days
Virus shedding 0 or 1 daye 7 to 8 (7.7 6 0.6) days 6 to 8 (7.0 6 1.0) days
Viremia Negative 7 to 8 (7.3 6 0.6) days 8 to 10 (9.3 6 1.2) days
a Mean 6 standard deviation shown in parentheses.
b Nasal discharge was not recorded in a foal (EI-4).
c Submandibular lymph nodes.
d Swelling of the lymph nodes was not recorded in two foals (EI-4 and EI-5).
e LacZ-positive virus was isolated only from a horse (EI-1) on day 2 postinoculation.
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the lacZ DNA (Table 1). Both 188 bp of the gB sequence
of EHV-1 and 377 bp of the lacZ sequence were amplified
only from DNA extracted from submandibular lymph
nodes of horse EI-3 by nested PCR (Fig. 4), and no
amplification of the gB- and/or the lacZ-specific se-
quences was detected from the other 29 samples, in-
cluding the trigeminal ganglion samples as well as from
a negative control water. On the other hand, the gB and
the lacZ sequences were amplified from the control
DNAs of the 89c25p and DgEDgI-lacZ strains, respec-
tively (Fig. 4). The gB sequence was also amplified from
DgEDgI-lacZ DNA, but no lacZ product was amplified
from 89c25p DNA by nested PCR (data not shown). After
challenge with the gE-gI-rev strain, on the other hand,
EHV-1 strains were isolated consecutively for 7 to 8 days
from day 1 and for 7 to 8 days from days 2–4 postchal-
lenge from nasal and blood samples, respectively (Table
4). These findings closely resembled the results of virus
isolation from gE-gI-rev-inoculated control foals (R-1–R-
3), as shown in Tables 3 and 4. The results suggested
that prior intranasal inoculation of foals with the DgEDgI-
lacZ strain had little effect in reducing the duration of
virus shedding and viremia after infection with the viru-
lent EHV-1.
Antibody responses of horses
Antibody responses of horses to EHV-1 detected by
serum neutralization (SN) and CF tests are shown in
Table 5. SN antibody to EHV-4 was not detected in the
serum of any horses throughout the study. None of the
six horses inoculated with the DgEDgI-lacZ strain exhib-
ited SN antibody response to EHV-1, and two of them
exhibited a weak CF antibody response at a 3-week
point (EI-3) and from 3 weeks (EI-1) after the inoculation
of DgEDgI-lacZ strain. On the other hand, two of the three
foals inoculated with the gE-gI-rev strain exhibited SN
antibody response to EHV-1 from 2 (R-3) and 3 weeks
(R-1) after the inoculation, and CF antibody responses
were recorded in all of these foals from 2 weeks after the
inoculation of gE-gI-rev strain. After the challenge with
the gE-gI-rev strain, SN antibody responses of the foals
inoculated 4 weeks prior with the DgEDgI-lacZ strain
were similar to those of the control foals (R-1–R-3). How-
ever, CF antibody responses observed in the DgEDgI-
lacZ-inoculated foals after challenge were detected one
week earlier and were higher in titer compared to those
of the control foals. The results indicated that an anam-
nestic boost in CF antibody response, but not in SN
antibody response, did occur following challenge with a
virulent EHV-1 in foals immunized intranasally with the
DgEDgI-lacZ strain.
DISCUSSION
We describe the construction of a recombinant EHV-1
with a deletion in the gE and gI genes and its revertant
and some of the biological characteristics of these vi-
ruses identified in in vitro and in vivo studies. Insertion of
the lacZ gene of E. coli replaced almost the entire coding
FIG. 4. Ethidium bromide-stained agarose gel of representative
nested PCR products. Lanes 1–3, EHV-1 gB-specific primer pairs (see
Table 1) used for the nested PCR; lane 4, DNA size standard, 50- to
2000-bp ladder (Bio-Rad Laboratories, CA); lanes 5–7, E. coli LacZ-
specific primer pairs used. The following templates were employed:
Lane 1, EHV-1 89c25p DNA; lanes 2 and 5, DNA sample extracted from
submandibular lymph nodes of horse EI-3; lanes 3 and 6, DNA sample
extracted from the trigeminal ganglion of horse EI-3; lane 7, EHV-1
DgEDgI-lacZ DNA.
TABLE 4
EHV-1 Isolation from Foals after Inoculation with gE-gI-rev Strain
Foal
Days after inoculation of gE-gI-rev strain
0 1 2 3 4 5 6 7 8 10 12 14–21
DgEDgI-lacZ-inoculated foals
EI-4 — Na NMb NM NM NM NM NM NM — — —
EI-5 — N N NM NM NM NM NM M M — —
EI-6 — N N N NM NM NM NM NM M — —
Control foals
R-1 — NM NM NM NM NM NM NM M M — —
R-2 — NM N NM N NM NM NM NM M — —
R-3 — N N NM NM NM NM M M M M —
a EHV-1 was isolated from a nasal swab.
b EHV-1 was isolated from a peripheral monocyte fraction.
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sequence for the gI gene, the promoter for the gE gene,
and most of the gE 59 sequence. Subsequently, the in-
serted lacZ gene was replaced by the deleted EHV-1
sequence in the recombinant. The resulting deletion vi-
rus, DgEDgI-lacZ, and its revertant, gE-gI-rev, were veri-
fied by PCR, DNA sequencing, and Southern blot analy-
ses. Serial passage of EHV-1 in nonequine cell cultures
has been shown to result in alterations in the viral DNA
(Allen et al., 1983). As expression of the lacZ gene was
hardly detected in viable FHK cells in the presence of
X-gal, nonequine RK13 cells were used for the selection
of the mutant virus. However, no alteration in the EHV-1
genome except for that engineered in the gI/gE locus of
the Us segment was detected in the RE profiles and DNA
sequencing of the viral strains used in this study.
The functions of the gE and the gI of other herpesviruses
have been assessed using recombinant viruses lacking
either or both of these glycoprotein genes. Glycoproteins
gE and gI of herpesviruses have been shown to facilitate
cell-to-cell spread since the deleted viruses yield small
plaques compared to those of the parent viruses in the
case of HSV-1 (Neidhardt et al., 1987; Dingwell et al.,
1994), PRV (Jacobs et al., 1993), BHV-1 (Otsuka and Xuan,
1996), and FHV-1 (Sussman et al., 1995). The fact that the
DgEDgI-lacZ strain of EHV-1 produced significantly
smaller plaques in FHK cells than did the parent virus
suggested that gE and/or gI of the EHV-1 also facilitate
cell-to-cell spread of EHV-1. Furthermore, the time course
of replication of the DgEDgI-lacZ strain in FHK and RK13
cells was quite similar to that of the parent strain, not-
withstanding the low cell-to-cell infectivity, suggesting
that gE and gI of the EHV-1 are not involved in either the
process of virus maturation and release or virus attach-
ment and penetration. Compared to the virulent EHV-1,
the KyA strain of EHV-1, which lacks at least six genes
including gE and gI, also produced small plaques which
were, however, larger than those of the DgEDgI-lacZ
strain. Moreover, the KyA strain replicated to titers that
exceeded those of the virulent and the gE and gI deletion
mutant strains of EHV-1. Since the complete sequencing
of the KyA strain is not yet accomplished, the other
modifications in the KyA genome apart from the 3859-bp
deletion, including the coding sequences for gE and gI,
may account for its plaque size and its efficient growth in
cell culture.
A PRV gE/gI deletion mutant derived from a virulent
PRV (Ka) strain exhibited reduced virulence, but still
possessed the ability to kill young pigs following intra-
nasal inoculation (Mettenleiter et al., 1987). Similarly,
mild clinical signs were observed in cats inoculated
oronasally with the recombinant FHV-1, in which the
genes for gE and gI were deleted (Kruger et al., 1996).
TABLE 5
Antibody Titers against EHV-1 Detected in Nine Horses Inoculated with EHV-1 Strains DgEDgI-lacZ and/or gE-gI-rev
Horse Test a
Antibody titers at indicated weeks after inoculation of DgEDgI-lacZ strain
0 1 2 3 4b(0) 5(1) 6(2) 7(3) 8(4)
DgEDgI-lacZ-inoculated horses
EI-1 SN ,1:5 ,1:5 ,1:5 ,1:5 ,1:5
CF ,1:4 ,1:4 ,1:4 1:4 1:4
EI-2 SN ,1:5 ,1:5 ,1:5 ,1:5 ,1:5
CF ,1:4 ,1:4 ,1:4 ,1:4 ,1:4
EI-3 SN ,1:5 ,1:5 ,1:5 ,1:5 ,1:5
CF ,1:4 ,1:4 ,1:4 1:4 ,1:4
EI-4 SN ,1:5 ,1:5 ,1:5 ,1:5 ,1:5 ,1:5 1:5 1:5 NDc
CF ,1:4 ,1:4 ,1:4 ,1:4 ,1:4 1:32 1:128 1:128 ND
EI-5 SN ,1:5 ,1:5 ,1:5 ,1:5 ,1:5 ,1:5 1:5 1:5 1:5
CF ,1:4 ,1:4 ,1:4 ,1:4 ,1:4 1:32 $1:256 1:128 1:128
EI-6 SN ,1:5 ,1:5 ,1:5 ,1:5 ,1:5 ,1:5 ,1:5 1:5 ,1:5
CF ,1:4 ,1:4 ,1:4 ,1:4 ,1:4 1:16 $1:256 1:128 1:128
Control foals
R-1 SN ,1:5 ,1:5 ,1:5 1:5 1:5
CF ,1:4 ,1:4 1:32 1:64 1:32
R-2 SN ,1:5 ,1:5 ,1:5 ,1:5 ,1:5
CF ,1:4 ,1:4 1:32 1:32 1:32
R-3 SN ,1:5 ,1:5 1:10 1:10 ND
CF ,1:4 ,1:4 1:32 1:32 ND
a Serum neutralization (SN) tests were conducted using EHV-1 89c25 strain. Complement fixation (CF) tests were conducted using an antigen
prepared from the EHV-1 HH-1 strain.
b Challenge of EHV-1 gE-gI-rev strain was conducted in 3 DgEDgI-lacZ-inoculated foals (EI-4 to EI-6) and 3 control foals (R-1 to R-3). Weeks after
challenge of gE-gI-rev strain are represented in parentheses.
c Not done.
74 MATSUMURA ET AL.
Therefore, the findings that horses inoculated intrana-
sally with a high dose of the recombinant EHV-1 strain,
DgEDgI-lacZ, exhibited no clinical signs were unex-
pected (Table 3). Furthermore, since the gE-gI revertant
virus caused respiratory symptoms typical of EHV-1 in-
fection in foals, it would appear that gE and gI may be
important factors in EHV-1 virulence. These findings also
suggest that the attenuated nature of the KyA strain may
have resulted from the deletion of gE and gI genes
(Flowers and O’Callaghan, 1992).
After the inoculation of six horses with the DgEDgI-
lacZ strain, virus replication of the DgEDgI-lacZ strain in
the upper respiratory tract was detected in only one
(EI-1) animal (Table 3). However, amplification of the DNA
sequences of the DgEDgI-lacZ strain was confirmed in
submandibular lymph nodes collected from one (EI-3) of
the three horses autopsied 4 weeks after the DgEDgI-
lacZ inoculation. EHV-1 has been found to establish
latency in lymphoid tissues draining the respiratory tract
(Welch et al., 1992), and recent reports indicated that
EHV-1 establishes latency within the trigeminal neurons
(Slater et al., 1994; Baxi et al., 1995). Although limited
replication in the respiratory tract and no viremia were
observed in horses inoculated with the DgEDgI-lacZ
strain, the DgEDgI-lacZ strain may possess the ability to
establish latency or to persist in lymph nodes. Although
sequences of neither the EHV-1 gB gene nor the lacZ
gene were amplified from trigeminal ganglia of three
horses inoculated with the DgEDgI-lacZ strain, further
investigation will be necessary to ascertain whether the
gE/gI deletion virus can replicate and establish latency in
the central nervous system of the equine.
The antibody responses against EHV-1 were weak or
undetectable in six horses after inoculation with the
DgEDgI-lacZ virus. However, an anamnestic boost in CF
antibody response in three DgEDgI-lacZ-inoculated foals
(Table 5) and protection from manifestation of nasal dis-
charge and swelling of submandibular lymph nodes in
one (EI-4) and two (EI-4 and EI-5) of the three foals,
respectively (Table 3), were observed after the challenge.
On the other hand, the SN antibody response to EHV-1
and the duration of the virus isolation from both nasal
swab and peripheral blood samples of the DgEDgI-lacZ-
inoculated foals after the challenge were similar to those
observed in the control foals (Tables 4 and 5). In our
previous study (Matsumura et al., 1996), duration of virus
shedding and viremia were shortened remarkably and a
higher and earlier SN antibody response to EHV-1 was
observed in the KyA-inoculated horses after the chal-
lenge with the pathogenic EHV-1 89c25 strain compared
to those of the control horses. The results of the present
study indicated that abilities of DgEDgI-lacZ to stimulate
the humoral antibody response and to confer protectivity
against the virulent EHV-1 infection in intranasally inoc-
ulated horses were rather weak compared to those of
the virulent and the KyA strains. In this regard, a similar
SN antibody response was observed in cats inoculated
oronasally with the recombinant FHV-1 defective in gE
and gI genes, in which no SN antibody response was
recorded on day 21 postinoculation (Kruger et al., 1996).
However, subcutaneous administration of the recombi-
nant FHV-1 induced SN antibody titers of cats to a level
as high as that of virulent FHV-1 on day 21 postinocula-
tion. Similarly, intramuscular inoculation with BHV-1 mu-
tants induced good SN antibody titers in cattle compared
to intranasal inoculation (Liang et al., 1997). Although
natural postnatal EHV-1 infection occurs via the respira-
tory route, different routes of inoculation may increase
the immunogenicity of the recombinant EHV-1 defective
in the gE and gI genes in horses.
The results from this study demonstrate that the gE
and gI genes of EHV-1 are important virulence factors
and that an EHV-1 mutant defective in these genes is
safe if inoculated intranasally in horses. Since the gE
and gI genes of other herpesviruses are associated
with neurovirulence (Neidhardt et al., 1987; Card et al.,
1992; Kritas et al., 1994) and since EHV-1 can cause
nervous disorders in infected horses, deletion of the
nonessential gE and gI genes may be important in
developing safe recombinant EHV-1 vaccines and
EHV-1-based vaccine vectors. To elucidate the func-
tions of the gE and gI genes of EHV-1 more precisely,
construction of EHV-1 recombinants deleted with ei-
ther of gE and gI genes is under way.
MATERIALS AND METHODS
Viruses, cells, and media
The EHV-1 strain 89c25p, a plaque-purified strain of a
low-passaged field strain, 89c25, was used as a parent
virus to construct the EHV-1 mutant. The strain, 89c25,
was isolated from a racehorse involved in the epizootic
of EHV-1 respiratory infection in 1989; during this
epizootic some of the infected horses manifested ner-
vous disorders (Matsumura et al., 1992, 1994). The 89c25
strain induces respiratory infection in yearlings (Ma-
tsumura et al., 1996), and fetal infection results from
experimental infection of pregnant mares (unpublished
data). Neither the plaque-purified nor the original 89c25
strain has been passaged in nonequine cells. The EHV-1
89c25 strain and an EHV-4 strain, TH20, the Japanese
prototype of EHV-4 (Kawakami et al., 1962), were used to
detect neutralizing antibodies to EHV-1 and EHV-4, re-
spectively, in the sera of experimentally infected horses.
For a preparation of complement fixation (CF) antigen,
EHV-1 strain HH-1, the Japanese prototype of EHV-1
(Kawakami et al., 1970), was used. An EHV-1 laboratory
strain, KyA, was also used as a gI- and gE-negative
reference strain of EHV-1 (Flowers and O’Callaghan,
1992).
Fetal horse kidney (FHK, within the seventh passage
history from primary culture) cells were used throughout
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the study except for selection of a mutant virus, for which
RK13 (an established cell line of rabbit kidney) cells were
used. FHK and RK13 cells were grown in Eagle’s mini-
mum essential medium (EMEM) supplemented with 10%
fetal calf serum (FCS) and antibiotics. Both FHK and
RK13 cells were used for one-step growth experiments.
RK13 and MDBK (an established cell line of bovine kid-
ney) cells grown in EMEM supplemented with 10% calf
serum and antibiotics were used for virus isolation from
samples taken from experimentally infected horses.
Plasmids and cloning
Molecular cloning procedures were essentially as de-
scribed by Sambrook et al. (1989). The viral DNA of
EHV-1 89c25p strain was extracted from infected FHK
cells as described previously (Matsumura et al., 1996).
Digestion of 89c25p DNA with SmaI and BamHI yielded
a 5.8-kb fragment, deduced from the complete DNA se-
quence of EHV-1 Ab4p (Telford et al., 1992) to include
genes gI and gE. The 5.8-kb fragment was cloned into
the HincII and BamHI sites of plasmid pUC19, and the
recombinant plasmid was designated as pSma-Bam
(Fig. 1). Plasmid pSma-Bam was confirmed to contain the
EHV-1 fragment corresponding to the SmaI–BamHI (nu-
cleotides (nt) 131,238 to 137,006) fragment of EHV-1 Ab4p
DNA by restriction enzyme (RE) and DNA sequence anal-
yses. Plasmid pCH110 containing the Escherichia coli
lacZ gene under the SV40 early promoter control was
purchased from Pharmacia Inc. (NJ).
Homologous recombination and
recombinant screening
Linearized donor plasmid DNA (20 mg) was mixed with
FHK cell suspensions [2 3 106 cells/0.8 ml phosphate-
buffered saline (PBS)] infected 1 h previously with the
89c25p strain at a m.o.i. of 0.02, and the mixture in a
0.4-cm cuvette was electroporated (0.3 kV, 250 mF) using
gene transfer equipment (Gene Pulser, Bio-Rad Labora-
tories, CA). Transfected cells were grown in 6-well cul-
ture plates at 37°C in a 5% CO2 atmosphere and were
harvested with a cell scraper at 4 days when cytopathic
effects (CPE) appeared. Cells were disrupted by three
freeze–thaw cycles and cleared by centrifugation. To
confirm whether the resulting virus stocks contained a
mutant virus expressing the lacZ gene, serially diluted
virus stocks were inoculated onto FHK monolayer in
6-well plates, and cells were cultured for 3 days with
EMEM containing 0.75% methylcellulose and 5% FCS.
The cells were then fixed and stained with 5-bromo-4-
chloro-3-indolyl-b-D-galactopyranoside (X-gal; Takara
Biomedicals, Japan) by the method of Sanes et al. (1986)
with a slight modification. After one wash with PBS, cells
were fixed with 2% (v/v) formaldehyde and 0.2% glutaral-
dehyde solution in PBS for 5 min at room temperature,
washed twice with PBS, and incubated with a staining
solution consisting of 5 mM potassium ferricyanide, 5
mM potassium ferrocyanide, 2 mM MgCl2, and 1 mg/ml
of X-gal in PBS at 37°C for 3 h. The cells that stained blue
were regarded as positive for the expression of lacZ
gene.
Selection of the mutant virus expressing the lacZ gene
was conducted by seeding appropriately diluted virus
stocks on RK13 cells in 90-mm dishes. After 3 days
incubation at 37°C with the overlay EMEM containing 5%
FCS and 0.9% agar, the cells were further overlaid with
the 0.9% agar medium containing 0.5 mg/ml of X-gal and
incubated at 37°C for 24 to 48 h. Blue plaques containing
recombinants were isolated and inoculated again onto
RK13 cells. This blue plaque cloning procedure was
repeated until 100% of the plaques in fixed cells were
positive for X-gal staining. Subsequently, purified virus
was passaged on FHK cells to yield virus stocks for
further experiments. Similarly, a revertant virus gener-
ated by homologous recombination between the mutant
virus and plasmid pSma-Bam DNA was selected by
white plaque cloning on RK13 cells under the presence
of X-gal in the overlay medium.
Polymerase chain reaction (PCR) and
DNA sequencing
Primers listed in Table 1 were used in PCR and DNA
sequencing to identify the deletion of gI and gE se-
quences and the insertion of lacZ gene in a deletion–
insertion mutant and to confirm the stability of the EHV-1
sequences at the junction sites (SmaI and BamHI sites)
of homologous recombination within the mutant virus
genome. The primers were synthesized with the Applied
Biosystems DNA synthesizer (Model 392). In addition,
nested PCR was conducted to detect the viral DNA in
some autopsied samples collected from experimentally
infected horses. PCR was carried out in a volume of 50 ml
containing 10 mM Tris–HCl, pH 8.3, 50 mM KCl, 1.5 mM
MgCl2, 0.001% (w/v) gelatin, 200 mM each dNTP, 1.0 mM
each primer, an appropriate amount of DNA sample, and
1.25 units of Taq polymerase (Perkin–Elmer, ABI, Japan).
DNA amplification was performed for 35 cycles, each
consisting of denaturation at 94°C for 75 s, annealing at
60°C for 90 s, and extension at 72°C for 90 s. Sequenc-
ing reactions were carried out with cycle sequencing kits
(Perkin–Elmer, ABI, Japan), and the labeled DNA was
sequenced with the Applied Biosystems DNA Sequencer
(Model 373A).
Southern blot hybridization
Digoxigenin (DIG)-labeled pSma-Bam and pCH110
DNAs were used as probes for hybridization. Viral
DNA fragments digested with BamHI were separated
on agarose gels by electrophoresis and transferred to
nylon membranes as described by Sambrook et al.
(1989). Hybridization assays and chemiluminescent
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detection of the probed fragment(s) were performed
using the DIG luminescent detection kit under condi-
tions recommended by the manufacturer (Boehringer
Mannheim, FRG).
Plaque size measurement
Appropriately diluted viruses were inoculated onto
FHK monolayers in 35-mm dishes (Corning Inc., Corning,
NY). Following 1 h adsorption, cells were overlaid with
EMEM containing 0.75% methylcellulose and cultured for
3 and 5 days. Cells were then fixed and stained with 0.2%
crystal violet or 1 mg/ml X-gal. Plaque-size measure-
ments were performed using the Electronic Plate Reader
AD001 (Alta Diagnostic Machines Ltd., Birmingham, En-
gland). The Student’s t test was employed to compare the
means of plaque sizes (n 5 20) of examined viruses.
Time course of viral growth
Monolayers of FHK and RK13 cells prepared in 6-well
plates were inoculated with virus samples at a m.o.i. of 4
plaque-forming unit (PFU)/cell. After 1 h adsorption, cells
were washed three times with EMEM and incubated at
37°C in a 5% CO2 atmosphere in 2 ml/well of EMEM with
2% FCS. At various intervals after inoculation, culture
fluids with scraped cells were centrifuged to sediment
the infected cells. The supernatants were used as the
extracellular samples. Following two washes with
EMEM, the cell pellets were resuspended in 2 ml of
EMEM with 2% FCS and subjected to three freeze–thaw
cycles. After centrifugation, the resulting supernatants
were used as the intracellular samples. Both extracellu-
lar and intracellular samples were titrated for viral infec-
tivity.
Animal experiments
To assess the virulence of the viruses, six young
horses [three half-bred weanling horses aged 9 months
(designated EI-1, EI-2, and EI-3) and three colostrum-
deprived Thoroughbred foals aged 71–85 days (desig-
nated EI-4, EI-5, and EI-6)] were inoculated intranasally
with the deletion mutant, and three colostrum-deprived
Thoroughbred foals aged 68–77 days (designated R-1,
R-2, and R-3) were inoculated intranasally with the rever-
tant. By confirmation that the revertant was as virulent as
the parent EHV-1 (see Results), three foals inoculated
with deletion mutant virus (EI-4–EI-6) were challenged
with the revertant 4 weeks later. All foals (EI-4–EI-6 and
R-1–R-3) were apart from their dams for 24 h after birth,
during which time the foals were fed a commercial milk
substitute and the dams’ udders were regularly stripped
out to remove the immunoglobulin-rich colostrum, as
described by Jeffcot (1973). All horses were free of neu-
tralizing antibodies against EHV-1 and EHV-4, which are
antigenically cross-reactive and cross-protective (Allen
and Bryans, 1986). Rectal temperatures were recorded
twice a day, and clinical signs were recorded at the time
of sample collection. Three conventionally reared horses
(EI-1–EI-3) infected with the deletion mutant virus were
autopsied on days 27–28 postinoculation to detect the
mutant virus distribution. For virus isolation, nasal swab
and peripheral blood samples were collected daily for
the first week after the inoculation or the challenge,
every other day for the second week, and twice a week
thereafter from each horse. Samples collected at au-
topsy were as described previously (Matsumura et al.,
1996). Serum samples were collected at weekly intervals
and stored at 220°C until use.
Virus isolation
Virus isolation was conducted immediately after the
sample collection. Preparations of inocula from collected
samples for virus isolation were described previously
(Matsumura et al., 1996). Approximately 106 mononuclear
cells fractionated using Lymphoprep (Nycomed, Oslo,
Norway), 0.5 ml of nasal and autopsied fluid samples,
and approximately 10 mg of minced tissue samples were
cocultured with suspended cells in 25-cm2 flasks (Corn-
ing Inc., Corning, NY). Flasks were incubated at 37°C
and observed for CPE daily for a week.
Assay for serum antibody to EHV-1 and EHV-4
For detection of type-specific antibody to EHV-1 and
EHV-4, plaque neutralization tests were conducted as
described previously (Matsumura et al., 1996). CF assays
were also carried out to detect antibody reactive with
both EHV-1 and EHV-4, as described by Sugiura et al.
(1987).
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